• Explore /
  • Poster
  • / CDK4/6 inhibitors outcomes in patients with advanced breast cancer based on HER2-low expression.

CDK4/6 inhibitors outcomes in patients with advanced breast cancer based on HER2-low expression.

Abstract Poster

Authors

null

Laura Sabina Lapuchesky

Cramer 1180, CABA, Argentina

Laura Sabina Lapuchesky , Marcos Bortz , Federico Waisberg , Diego Hernán Enrico , Luisina Ines Bruno , Cristian Alexis Ostinelli , Sergio Gabriel Rivero , Andres Rodriguez , Martin Zarba , Martin Loza , Verónica Yamila Fabiano , Mora Amat , Maria Teresa Pombo , Maria Laura Noro , Federico Andrés Coló , Reinaldo D. Chacon , Matias Rodrigo Chacon , Jorge Carlos Nadal , Adrian Nervo , Maria Victoria Costanzo

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Breast Cancer—Metastatic

Track

Breast Cancer

Sub Track

Hormone Receptor-Positive

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 1056)

DOI

10.1200/JCO.2022.40.16_suppl.1056

Abstract #

1056

Poster Bd #

434

Abstract Disclosures

Similar Posters

First Author: Peter A. Fasching

Poster

2019 ASCO Annual Meeting

NMR-metabolite-resonance signature to predict HR+ breast cancer patient response to CDK4/6 inhibitors.

NMR-metabolite-resonance signature to predict HR+ breast cancer patient response to CDK4/6 inhibitors.

First Author: Bo Zhang

First Author: Mafalda Oliveira

First Author: Rachel M. Layman